Literature DB >> 14569133

CHEK2 1100delC and colorectal cancer.

O Kilpivaara, P Laiho, L A Aaltonen, H Nevanlinna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14569133      PMCID： PMC1735285          DOI： 10.1136/jmg.40.10.e110

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  13 in total

1.  CHEK2 I157T associates with familial and sporadic colorectal cancer.

Authors:  O Kilpivaara; P Alhopuro; P Vahteristo; L A Aaltonen; H Nevanlinna
Journal:  J Med Genet       Date:  2006-07       Impact factor: 6.318

Review 2.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

3.  The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families.

Authors:  Ana Sánchez de Abajo; Miguel de la Hoya; Javier Godino; Vicente Furió; Alicia Tosar; Pedro Pérez-Segura; Eduardo Díaz-Rubio; Trinidad Caldés
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.

Authors:  Yue Wang; Bo Dai; Dingwei Ye
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  CHEK2 is a multiorgan cancer susceptibility gene.

Authors:  C Cybulski; B Górski; T Huzarski; B Masojć; M Mierzejewski; T Debniak; U Teodorczyk; T Byrski; J Gronwald; J Matyjasik; E Zlowocka; M Lenner; E Grabowska; K Nej; J Castaneda; K Medrek; A Szymańska; J Szymańska; G Kurzawski; J Suchy; O Oszurek; A Witek; S A Narod; J Lubiński
Journal:  Am J Hum Genet       Date:  2004-10-18       Impact factor: 11.025

6.  Alterations of Chk1 and Chk2 expression in colon cancer.

Authors:  Magdalena Stawinska; Adam Cygankiewicz; Radzislaw Trzcinski; Michal Mik; Adam Dziki; Wanda M Krajewska
Journal:  Int J Colorectal Dis       Date:  2008-08-05       Impact factor: 2.571

7.  A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.

Authors:  Deborah Thompson; Sheila Seal; Mieke Schutte; Lesley McGuffog; Rita Barfoot; Anthony Renwick; Rosalind Eeles; Nayanta Sodha; Richard Houlston; Susan Shanley; Jan Klijn; Marijke Wasielewski; Jenny Chang-Claude; P Andrew Futreal; Barbara L Weber; Katherine L Nathanson; Michael Stratton; Hanne Meijers-Heijboer; Nazneen Rahman; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12       Impact factor: 4.254

8.  The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN).

Authors:  Kathrin Scheckenbach; Galatia Papadopoulou; Thomas K Hoffmann; Adam Chaker; Henning Bier; Jörg Schipper; Vera Balz; Martin Wagenmann
Journal:  J Negat Results Biomed       Date:  2010-12-25

9.  Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Authors:  Kirsi M Kuusisto; Aleksandra Bebel; Mauno Vihinen; Johanna Schleutker; Satu-Leena Sallinen
Journal:  Breast Cancer Res       Date:  2011-02-28       Impact factor: 6.466

10.  CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum.

Authors:  Anna Isinger; Misha Bhat; Ake Borg; Mef Nilbert
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.